Imaavy FDA Approval Makes J&J Drug First wAIHA Treatment

What the FDA approved

The U.S. Food and Drug Administration has widened the label for Johnson & Johnson's nipocalimab-aahu, sold as Imaavy, to cover warm autoimmune hemolytic anemia (wAIHA). The new indication applies to adults and to children 12 and older who are taking corticosteroids now or have taken them before.21 With this decision, Imaavy becomes the first drug the agency has approved specifically for wAIHA, which is the most common type of autoimmune hemolytic anemia.21 Johnson & Johnson announced the approval on August 24, 2026, and the FDA posted its own summary the following day.2421

Imaavy was already on the market. Regulators first cleared it in April 2025 for generalized myasthenia gravis in patients 12 and older who test positive for anti-acetylcholine receptor or anti-MuSK antibodies. The wAIHA indication is its second.27 The supplemental application went through the agency's expedited channels. The FDA gave the indication Fast Track, priority review and orphan designations, and named Janssen Biotech as the approval holder.21 Priority review was granted in April, according to trade press that followed the filing.2226

The disease and the gap in treatment

In wAIHA, immunoglobulin G (IgG) autoantibodies latch onto a patient's red blood cells and mark them for destruction. The result is anemia and heavy fatigue.24 The FDA estimates the condition affects about 1 to 3 people per 100,000 each year and notes it can appear at any age.21 Other reporting adds that about 1 in 8,000 people live with the disease, that it becomes more common after age 50, and that complications include venous thromboembolism, acute kidney injury and infection.23

All the coverage describes the treatment landscape in much the same way. Doctors have relied on corticosteroids and broad immunosuppressants, none of them approved for wAIHA, and these drugs dampen the whole immune system instead of targeting the antibodies that drive the disease.2423 Some physicians have also used B-cell-directed therapies off-label. A J&J executive said before the approval that existing therapies do not address the underlying cause of the disease.22 Given this, the "first approved" label is more than marketing. It gives hematologists an on-label option with randomized evidence behind it for a disease that has had neither.

How the drug works

Nipocalimab is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn). That lowers the amount of IgG circulating in the body, including the harmful autoantibodies, while leaving B-cell function and the broader immune system largely intact.2328 The approach suits wAIHA well, because the disease is driven by IgG. Lower the IgG and, in principle, fewer red cells get tagged for destruction. Imaavy is not the only FcRn blocker. In myasthenia gravis it competes with UCB's rozanolixizumab and Argenx's efgartigimod products.3 In wAIHA, at least for now, it has no approved competitor.

The ENERGY trial: a real benefit, but a modest one

The approval is based on ENERGY, a 24-week, randomized, double-blind, placebo-controlled Phase 2/3 study.21 Patients had confirmed wAIHA for at least three months, hemoglobin below 10 g/dL, signs of active hemolysis and a positive direct antiglobulin test. Everyone had received prior or ongoing treatment for the disease.21 Patients could stay on stable doses of steroids or immunosuppressants during the study.27

The primary endpoint was strict. A durable hemoglobin response meant reaching at least 10 g/dL, with a rise of at least 2 g/dL from baseline held for 28 days or more and no rescue therapy.24 At the approved dose of 30 mg/kg by IV infusion every four weeks, 24% of patients met that bar, compared with 8% on placebo.21 More precise figures put it at 23.7% versus 7.7%, a 16-point difference with a 95% confidence interval of 0.1 to 31.9 and a one-sided p-value of 0.015.25

J&J's framing, which much of the coverage repeated, is that about three times as many treated patients responded.2628 That is accurate, but it can hide the absolute numbers. Roughly three in four patients on the approved dose did not reach a durable response within 24 weeks. And a confidence interval whose lower bound is barely above zero points to a statistically real effect whose size is not yet precisely known.25

The secondary results help the case. Mean hemoglobin rose by about 1 g/dL as early as week 1 in the approved-dose group.2327 The median time to a first response was 4.1 weeks with the drug, versus 12.1 weeks with placebo.23 On the FACIT-Fatigue scale, scores at week 24 were 3.5 points better than placebo.26 For a disease where exhaustion is a central complaint, that matters.

Where the reports disagree

The coverage does not agree on how many patients were in the trial. The FDA says 118 patients were randomized across three arms: 30 mg/kg every four weeks, 15 mg/kg every two weeks, or placebo.21 Several trade outlets, apparently following J&J's materials, say 115 adults.2327 One hematology outlet reports only the 77 patients in the approved-dose and placebo arms.25 These counts may just reflect different analysis sets, but the gap is worth noting.

The bigger difference is in what each account chose to include. The FDA's summary says plainly that the 15 mg/kg every-two-weeks regimen did not produce more durable responses than placebo.21 Most company-driven coverage leaves this out and focuses on the approved dose. Our reading is that the failed arm is informative. It suggests that the dose and how often it is given matter a great deal, and it is a reason to be careful about the size of the benefit until longer-term and real-world data arrive.

There is also a gap for younger patients. ENERGY enrolled adults only. Approval for ages 12 to 17 rests on extrapolation and pharmacokinetic bridging, not on efficacy data from adolescents.23 This is a common regulatory approach for rare diseases, but doctors treating teenagers should know about it.

Safety and practical use

The most common side effects at the approved dose, each seen in at least 10% of patients, were peripheral edema, diarrhea and fever. J&J says this matches the drug's record in myasthenia gravis.28 Guidance for pharmacists also stresses watching for infections, avoiding live vaccines, and managing hypersensitivity or infusion reactions.27 Imaavy comes in single-dose vials for IV infusion, and J&J offers a patient assistance program to help with payer approvals.27 Monthly infusions are a logistical burden compared with oral steroids, and they will shape which patients doctors pick first.

What it means for J&J

The approval fits a busy regulatory year for J&J. The company has also won approvals this year for its oral IL-23 psoriasis drug Icotyde and for new multiple myeloma combinations, among others.218 For nipocalimab, the bigger plan is to build one molecule into a franchise across IgG-driven diseases. The drug holds Fast Track, Orphan Drug and Breakthrough Therapy designations in several antibody-mediated conditions, including hemolytic disease of the fetus and newborn and Sjögren's disease.23 J&J has said it will keep studying the drug in rheumatology, rare autoantibody diseases and maternal-fetal conditions.26

That is why the wAIHA label matters more than its patient numbers suggest. Each new indication adds to the evidence that FcRn blockade can work across many autoimmune diseases, and makes later filings easier to argue.

Our read

This is a real regulatory milestone, but its clinical importance is still unproven. The FDA filled an empty treatment category based on a stringent endpoint and a statistically significant result. Fast hemoglobin gains and better fatigue scores support the benefit. Still, the absolute response rate was modest, one dosing arm failed, and the adolescent indication is extrapolated. One trade analysis argued that guideline-backed steroid-first treatment is deeply entrenched, and that durability data after approval, more than the approval itself, will decide whether hematologists adopt the drug.28 We agree. In the near term, the drug will probably be used mainly in patients whose disease stays uncontrolled despite steroids, the group J&J itself highlighted.25 Whether it moves earlier in treatment depends on evidence that does not exist yet.